BMS, Sanofi Escape Plavix FCA Suit Under Escobar Standard
Bristol-Myers Squibb and Sanofi have escaped a whistleblower False Claims Act suit accusing them of prompting Medicaid overbilling through deceptive marketing of the blood thinner Plavix, after a New Jersey federal...To view the full article, register now.
Already a subscriber? Click here to view full article